How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cushing'S Syndrome Market
- By Treatment Type: Surgical Treatment, Pharmacological Treatment, Radiation Therapy, Combination Therapy
- By Drug Class: Adrenal Steroidogenesis Inhibitors, Pituitary-Directed Drugs, Glucocorticoid Receptor Antagonists, Combination Drugs
- By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
- By Etiology: ACTH-Dependent Cushing's Syndrome, ACTH-Independent Cushing's Syndrome
- By Diagnosis Method: Biochemical Tests, Imaging Techniques, Inferior Petrosal Sinus Sampling
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Treatment leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.172 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.180 →
Full report · locked preview
Everything inside the Cushing'S Syndrome Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 4
Drug Class 4
End-User 4
Etiology 2
Diagnosis Method 3
Companies profiled
Novartis AG
Recordati S.p.A.
HRA Pharma
Ipsen
Strongbridge Biopharma
Corcept Therapeutics
Pfizer Inc.
Mitsubishi Tanabe Pharma Corporation
Horizon Therapeutics
Chiasma Inc.
Bristol-Myers Squibb
Eli Lilly and Company
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Recordati S.p.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →HRA Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ipsen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Strongbridge Biopharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Corcept Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Horizon Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Chiasma Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Eli Lilly and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sanofi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,153M by 2033 · 7.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Treatment53.6
- Pharmacological Treatment19.0
- Radiation Therapy12.5
- Combination Therapy14.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$214.5M → $368.2M · 7.0%
Europe$149.5M → $280.2M · 8.2%
Asia Pacific$136.5M → $215.0M · 5.8%
Latin America$84.5M → $140.7M · 6.6%
Middle East and Africa$65.0M → $112.3M · 7.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.382026
7.392027
7.402028
7.422029
7.432030
7.442031
7.442032
7.472033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG15.5
- Recordati S.p.A.21.6
- HRA Pharma11.0
- Ipsen7.9
- Strongbridge Biopharma7.3
- Corcept Therapeutics8.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type15.2%
Drug Class17.4%
End-User27.4%
Etiology13.6%
Diagnosis Method26.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe25.1
- Asia Pacific19.3
- Latin America12.6
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 78 | 91 | 85 | 89 | 87 | 74 | 84 |
| Recordati S.p.A. | 85 | 79 | 83 | 82 | 83 | 76 | 81 |
| HRA Pharma | 72 | 64 | 75 | 74 | 78 | 73 | 73 |
| Ipsen | 72 | 59 | 63 | 61 | 73 | 68 | 66 |
| Strongbridge Biopharma | 54 | 71 | 66 | 54 | 76 | 52 | 62 |
| Corcept Therapeutics | 63 | 49 | 49 | 52 | 46 | 58 | 53 |
| Pfizer Inc. | 60 | 54 | 60 | 47 | 43 | 43 | 51 |
| Mitsubishi Tanabe Pharma Corporation | 45 | 37 | 55 | 49 | 51 | 46 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Recordati S.p.A.
- HRA Pharma
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Recordati S.p.A. | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| HRA Pharma | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Ipsen | ✓ | − | − | ◐ | ◐ | − |
| Strongbridge Biopharma | − | ◐ | − | − | ✓ | − |
| Corcept Therapeutics | − | − | − | − | − | − |
| Pfizer Inc. | ◐ | − | − | ◐ | − | ◐ |
| Mitsubishi Tanabe Pharma Corporation | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG84
2Recordati S.p.A.81
3HRA Pharma73
4Ipsen66
5Strongbridge Biopharma62
6Corcept Therapeutics53
7Pfizer Inc.51
8Mitsubishi Tanabe Pharma Corporation47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGRecordati S.p.A.
Challenger1
Strong scale, closing on the leaders.
HRA Pharma
Contender2
Focused players with pockets of strength.
IpsenStrongbridge Biopharma
Niche3
Specialists in a single segment or region.
Corcept TherapeuticsPfizer Inc.Mitsubishi Tanabe Pharma Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Cushing'S Syndrome Market — a $586M beachhead inside a $8.43B market.
Beachhead (SOM)$586Mobtainable near-term
Serviceable (SAM)$3.10Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Surgical Treatment
Best fit — highest urgency & budget in Treatment Type.
Economic buyer76 fit
Pharmacological Treatment
Strong fit — clear ROI and a fast path to value.
End user70 fit
Radiation Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cushing'S Syndrome Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified22%
Evaluation14%
Closed-won7%
$19.2KCAC
$105KLTV
5.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cushing'S Syndrome Market is a resilient opportunity — $5.26B by 2033, compounding at 4.9%.
TAM · 2025$3.60Btoday
TAM · 2033$5.26Bforecast
CAGR4.9%2027–2033
Cumulative$39.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.26BTotal addressable market
SAM$2.17BServiceable available market
SOM$363MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.9% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.26BLarge & growingTAM by 2033 at 4.9% CAGR
$2.17BServiceable nowreachable with today’s model
$363MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.10BBear3.2% CAGR
$5.26BBase4.9% CAGR
$6.73BBull6.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cushing'S Syndrome Market — a $5.20B market by 2033. Plan: grow share from 10.8% to 17.1%.
Market size · 2033$5.20Btotal addressable
Market CAGR9.4%2027–2033
Target share17.1%from 10.8% today
Revenue ambition$889Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 17.1% | Ahead |
| Revenue | $553M | $889M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 34.5% | 40.5% | On track |
| Customer retention | 85.3% | 93.6% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $126M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cushing'S Syndrome Market conversation — a $9.72B market you can size, segment and defend in minutes.
Market size · 2033$9.72Btotal opportunity
Growth7.7%CAGR to 2033
Addressable buyers988+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 2 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Novartis AGRecordati S.p.A.HRA PharmaIpsenStrongbridge BiopharmaCorcept TherapeuticsPfizer Inc.Mitsubishi Tanabe Pharma Corporation+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cushing'S Syndrome Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cushing'S Syndrome Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cushings Syndrome Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportCushion Film Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCushion Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportCushion Packing Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportCushion Pillow Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCushion Sewing Machine Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportCustard Apple Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCustody Service Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCustom Accumulators Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCustom- Africa and South Africa Investment Casting Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCustom Air Handler Market
Custom Air Handler Market is valued at USD 4.62 Billion in 2025 and is expected to reach USD 5.…
$4.6B market · 2025 base year
View reportCustom Ankle Foot Orthosis (AFO) Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.